The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity

Summary

The first preclinical demonstration that oral NR protects against diet-induced metabolic disease in mice, from the Auwerx laboratory. C57BL/6J mice fed a high-fat diet supplemented with 400 mg/kg/day NR showed markedly reduced weight gain, improved insulin sensitivity, and preserved glucose tolerance compared with high-fat-diet controls. NR-treated animals exhibited enhanced oxidative metabolism in skeletal muscle and brown adipose tissue, with increased mitochondrial biogenesis and activation of SIRT1 and SIRT3 signaling. Whole-body energy expenditure was elevated without changes in food intake or activity, consistent with increased thermogenic capacity. The effects mirrored those of resveratrol and PPAR-δ agonists but through the upstream mechanism of cosubstrate (NAD+) availability. The study directly motivated human NR trials in metabolic populations — obesity, prediabetes, NAFLD — and is the most-cited preclinical paper on NR's metabolic benefits. It also established the 400 mg/kg/day mouse dose (≈2 g/day human-equivalent) that shaped subsequent clinical trial dose selection.

For background on the compound studied here, see our NR precursor reference.

Frequently asked questions

What did Cantó et al. (2012) find about NR?

Oral NR at 400 mg/kg/day prevents high-fat-diet-induced obesity and insulin resistance in mice via SIRT1/SIRT3 activation and mitochondrial biogenesis. Source: Cantó C, Houtkooper RH, Pirinen E, et al. "The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity." Cell Metabolism, 2012.

What kind of study is Cantó 2012?

It is a mechanism study on NR published in Cell Metabolism in 2012. The first preclinical demonstration that oral NR protects against diet-induced metabolic disease in mice, from the Auwerx laboratory. C57BL/6J mice fed a high-fat diet supplemented with 400 mg/kg/day NR showed markedly reduced weight gain, improved insulin sensitivity, and preserved glucose tolerance compared with high-fat-diet controls. NR-treated animals exhibited enhanced oxidative metabolism in skeletal muscle and brown adipose tissue, with increased mitochondrial biogenesis and activation of SIRT1 and SIRT3 signaling. Whole-body energy expenditure was elevated without changes in food intake or activity, consistent with increased thermogenic capacity. The effects mirrored those of resveratrol and PPAR-δ agonists but through the upstream mechanism of cosubstrate (NAD+) availability. The study directly motivated human NR trials in metabolic populations — obesity, prediabetes, NAFLD — and is the most-cited preclinical paper on NR's metabolic benefits. It also established the 400 mg/kg/day mouse dose (≈2 g/day human-equivalent) that shaped subsequent clinical trial dose selection.

Where can I read the full Cantó 2012 paper?

The primary source is available on PubMed (PMID 22682224) and via DOI 10.1016/j.cmet.2012.04.022.

Access the full paper

Related research